Wednesday, 19 October 2016

Organ Preservation Solutions Market to Rise at 16.50% CAGR from 2019

Organ preservation solutions are used to preserve organs before transplantation procedure as these organs in external climate are vulnerable and also become dysfunctional once taken out from the human body. To preserve and maintain organs functionality for their further usage such as transplantation and research, organ preservation solutions are used. Increasing demand for organ transplantation procedures across the globe is expected to drive the growth of organ preservation solutions market. In addition, aging population will also propel the growth of organ preservation solutions market as the risk of organ failure in elderly people increases that augments the demand for organ transplants. Likewise, development of technologically advanced solutions for preserving organs will further accentuate the growth of organ preservation solutions market.

This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved. These solutions include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). The market for these solutions has been extensively analyzed based on number of organ transplant, efficiency and application area. The market size and forecast in terms of USD million for each product type has been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for each segment.

Based on the type of preservation techniques used to preserve organs, market has been segmented as hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). The market for these technologies has been extensively analyzed based on number of organ transplant, compatibility with solution and organs, and cost. The market size and forecast in terms of USD million for each product type has been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for each segment.

Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for this segment. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for each segment.

The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. In addition, major events have also been discussed in the section that have boosted the growth of the market and expected to further propel the growth during the forecast period. Also, this section covers market attractiveness analysis (by geography) for the year 2012 and Porter’s five forces analysis for the global ultrasound devices market. Market share (%) by revenue for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. In addition, the report also profiled key players of the market on various parameters such as business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K√∂hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc.

Browse Research Report on Global Organ Preservation Solutions Market:

Tuesday, 18 October 2016

Global Biosensors Market to Progress as Companies Aim at Human Optimization

Biosensors are the devices used for the detection of analyte and combines physiological detector with biological components. There are certain types of biosensors that include resonant mirror, electrochemical, surface plasmon resonance and light addressable potentiometric.The biosensors market is expected to witness the growth owning to wide range of applications in cardiac monitoring, diabetes monitoring, agriculture, drug recovery, environmental practices and others. 

Biosensors market is segmented into three aspects include- by applications, technologies and end use industries. The biosensor technology market include optical, electrochemical, thermistors and piezoelectric. The application segment covers wide range of biosensors applications such as medical testing, environmental, food toxicity, agriculture, industrial and others. The end user chapter include biosensors devices practiced by research laboratories, security and bio defense, home care diagnostic and others. 

This market is expected to show the single digit growth in CAGR by 2019.  Different companies are collaborating with universities to develop biosensors that are affordable, offer high precision and easy to use that acts as driving force for this market.In coming years, companies are investing and discovering non evasive decease monitors that are based on bio-sensing technologies.

Some of the key drivers for this market include rise in diabetic and aging population leading to chronic decease, increasing demand in point of care testing, miniaturization of sensors in healthcare.Diabetes testing is the largest market for biosensors in medical applications.  However, the challenge for this technology is high cost involvement in research and development.

Some of the market players in this industry are, Abbott Diagnostics, Roche Diagnostics, Nova Medical, M-Biotech, Hoffmann-La Roche, Medtronic Diabetes, Life sensors Inc., Agamatrix Inc., Bayer Diagnostics and Biacore among others.

Browse Research Report on Global Biosensors Market:

Monday, 17 October 2016

Lysosomal Acid Lipase Market Global Analysis and Forecast 2016 to 2024

The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. 

Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesterol esters and triglycerides. Patients with LAL deficiency have no or little LAL enzyme activity which results in the accumulation of fats within various body cells that leads to high cholesterol and triglycerides, and a very low HDL-cholesterol level. There are two main types of LAL disorder: early onset Wolman Disease and late onset CESD. Wolman disease is very rare, with an incidence of less than one in 100,000 live births. CESD is a less severe, later-onset disorder which can occur in adults at any stage in life, having an incidence of about one in 25 per million births. While Wolman disease is a relatively occurrence, the infants affected with it usually die within the first year of birth after experiencing growth failure, liver fibrosis, and cirrhosis. In late onset LAL deficiency, the accumulation of cholesteryl esters and triglycerides in blood vessels, vital organs, and other tissues of adults, results in progressive and multiple-organ damage which includes fibrosis, cirrhosis, liver failure, accelerated atherosclerosis, and cardiovascular disease. Since LAL disease has symptoms similar to many other diseases, for instance, heart disease, it is often misdiagnosed. The disease in its late onset form does not affect everyone equally and thus symptoms can vary from person to person, often manifesting as mild symptoms which consequently also makes the disease underdiagnosed worldwide. The biggest factor that shall drive the market is that currently, apart from a recently approved drug by U.S. FDA known as Kanuma (sebelipase alfa), there is no approved treatment available for the disease. Thus, tremendous business opportunity lies in the investment of finding therapies for treatment in this market. Lack of awareness regarding disease diagnosis and untimely treatment due to ignorance of symptoms may restrain the growth of the market.

The global market for lysosomal acid lipase (LAL) deficiency is segmented on basis of type of therapy, type of drug, disease indication and geography:

Segmentation by Type of Therapy (no. of surgeries)
  • Liver Transplant
  • Hematopoietic Stem Cell Transplant
Segmentation by Type of Drug
  • Statins and other dyslipidemia drugs
  • Sebelipase alfa (Kanuma)
Segmentation by Disease Indication
  • Wolman Disease
  • Cholesteryl ester storage disease (CESD)
LAL deficiency is a chronic progressive genetic metabolic disease associated with substantial morbidity as well as premature mortality. It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million of the general population. The current management practice for the disease involves taking lipid lowering medications such as statins, to overcome symptoms of lipid accumulation. However, progression of the disease often necessitates the patient to undergo a liver transplant. The market for lysosomal acid lipase (LAL) deficiency is segmented based on number of surgeries: for liver transplant and for hematopoietic stem cell transplant.  A liver transplant may give LAL patients respite from liver failure, but it does not tackle the underlying cause of the disease and may not stop disease progression in extra-hepatic organs, which include the heart and kidneys. However, it is still an option for patients who wish to increase chances of survival. Although hematopoietic stem cell transplant has been performed in a few infants with lysosomal acid lipase (LAL) deficiency, it has been associated with complications and the long term outcomes are unknown. Thus, the liver transplant segment shall witness more number of surgeries during the forecast period compared to the hematopoietic stem cell transplant segment. 

Based on disease indication, sebalipase alfa segment is expected to contribute largest share in global lysosomal acid lipase (LAL) deficiency treatment market due to it being the only approved mainstay treatment for the disease. Statins although helpful in symptom management for lysosomal acid lipase (LAL) deficiency, are not effective in completely preventing the progression of the disease, resulting in their estimated lower share in the market compared to sebalipase alfa. Moreover, the value garnering segment would be sebalipase alfa due to its higher cost of treatment and also being the preferred treatment due to it being the only approved drug for this indication. On the basis of disease indication, the market has been segmented into wolman disease and cholesteryl ester storage disease (CESD). The market for CESD is anticipated to be higher due to comparatively higher need in this segment.

On the basis of regional presence, global lysosomal acid lipase (LAL) deficiency treatment market is segmented into five key regions viz.  North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe are expected to lead the global lysosomal acid lipase (LAL) deficiency treatment market due to high prevalence of this rare disease.

Some of the major players in global lysosomal acid lipase (LAL) deficiency treatment market are Alexion Pharmaceutical Inc., AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.

Friday, 14 October 2016

Global Neurorehabilitation Devices Market Share, by Geography, 2016 & 2024

Players in the healthcare and medical devices industry have recognized the growing need for neurorehabilitation devices owing to the surging rise in the incidence of various neurological disorders. As a result, manufacturers of neurorehabilitation devices such as St. Jude Medical, Inc., Ekso Bionics Holding, Inc., Medtronic plc, Hocoma AG, Bioness, Inc., and AlterG, Inc. have begun offering a wide variety of technologically advanced and more effective devices, including brain-computer interfaces, wearable devices, neurorobotic systems, and non-invasive brain stimulators. Among the aforementioned companies, Transparency Market Research has found that Medtronic, St. Jude Medical, and Hocoma – the top three vendors catering to the demand for neurorehabilitation devices – together accounted for a 50% share in the global market.

“Over the past century, brain research has made tremendous progress and has almost been keeping up with the pace at which neurodevelopmental disorders are growing,” a TMR analyst states.

“Technological as well as scientific research is being carried out in various disciplines and sectors, demonstrating the potential of the neurorehabilitation devices market.

The goal of neurorehabilitation device manufacturers is to lessen the long-term disability of the patient, maximize their quality of life, and improve their overall psychosocial outcomes. Innovative strategies for various neurological disorders are being developed by integrating wearable technology, nanotechnology, robotics, Internet of Things, and non-invasive medical technologies with the neurorehabilitation. A case in point would be St. Jude Medical’s Proclaim ELITE. This is the first and only non-rechargeable and upgradeable spinal cord stimulation system that has received approval for the delivery of burst stimulation to relieve chronic pain that can be treated with neurorehabilitation.

“Strategic collaborations for business expansion is another crucial move manufacturers of neurorehabilitation devices have been making to tighten their hold on the global market,” the author of the study claims. Medtronic’s purchase of Sapiens Steering Brain Stimulation in August 2014 and its acquisition of Covidien plc in June 2014 has not only expanded Medtronic’s portfolio but also accelerated the company’s growth.

Dearth of Neurological Services a Deterrent in Low-income Countries

The surging incidence of neurological disorders, coupled by the rise in funding by private and government organizations have fueled the demand for neurorehabilitation devices, TMR states. These factors are anticipated to drive the opportunity in this market to rise at a 15.5% CAGR from 2016 to 2024. The value of the neurorehabilitation devices market is poised to increase from US$894.9 mn in 2015 to US$3.2 bn by the end of the forecast period.

“The fact that neurological resources and services are disproportionately scarce, especially in developing and low-income countries, acts as a major impediment to the growth of the neurorehabilitation devices market,” the analyst states. “Moreover, there is a high disparity in the number of trained and skilled professionals in comparison to the target population in emerging economies.” This, along with the high cost of rehabilitation therapy, gives rise to considerable challenges in the large-scale adoption of neurorehabilitation devices.

High Cost of Treatment is Likely to Restrict Wide-scale Adoption in APAC

North America and Europe are the largest revenue generators and dominated the global market in 2015. This can be primarily attributed to the growing prevalence of neurological conditions, improvement in technology, the rising awareness regarding neurorehabilitation devices and centers, and the presence of a well-established healthcare infrastructure. Although Asia Pacific is an immensely promising market for neurorehabilitation devices and is projected to emerge as the fastest developing regional market by 2024, it is the high cost of treatment that creates a barrier in the seamless adoption of these devices in Asia Pacific, leading to a major deterrent in the neurorehabilitation devices market.

Browse Research Report on Global Neurorehabilitation Devices Market:

Wednesday, 12 October 2016

Global Medical Transcription Services Market Driven by Rising Healthcare Automation

Medical transcription services have thus far been a niche within the healthcare industry. But as the automation wave sweeps across the healthcare industry, the role of medical transcription services is set to become exceedingly important. A concurrent standardization of medical reporting is being observed as healthcare outsourcing becomes a norm for the industry. In the midst of all of these changes, the medical transcription services market is expected to profit handsomely. Market intelligence firm Transparency Market Research (TMR) reckons that the global medical transcription market will generate revenues amounting to US$60.6 bn by 2019. The market’s valuation was pegged at US$41.4 bn in 2012. Expressed in terms of CAGR, this revenue growth stands at 5.60% CAGR from 2013 to 2019.

While there is no dearth of factors that will create a fertile ground for the growth of medical transcription services, one that will particularly disrupt the status quo is the growing migration to electronic health records (EHR) from a paper-heavy way of life in the healthcare sector. Here are a few important questions that companies in the medical transcription services market should consider when they plan for the future:

Q. How profound will the impact of EHR be on the global medical transcription services market?

While most companies in the medical transcription services market have thus far focused on the services aspect, the time is now ripe for companies for also venture into the product/software developed side of the business. Companies that already boast a firm footing in the medical transcription services market can leverage their existing expertise of processes and standards to create medical transcription software that is more intuitive, interoperable, and comprehensive. Changes to this end have already been observed with audio recorders being increasingly replaced by state-of-the-art speech recognition software. 

Integrating medical transcription platforms with mobile applications is yet another trend that will grow stronger in the years ahead. Case in point would be ZyDoc, a U.S.-based company that offers informatics and medical transcription services that offers hospitals web-based EHR data insertion and web-based transcription services. To meet this end, the company uses its proprietary TrackDoc Flow platform.

Q. Concerns about offshoring medical transcription continue to persist. How is this being tackled by companies in the industry?

The growing emphasis on profitability in the healthcare industry has prompted the offshoring of medical transcription services to countries such as the Philippines, India, and China. However, the fact remains that providing medical transcription services requires a high degree of familiarity with medical terms, skilled manpower, and a high degree of accuracy. These concerns continue to cast a shadow on the growth of the global medical transcription services market as they entail finding a reliable transcription services partner without threatening jobs in the home country. However, with global medical transcription services providers such as Nuance Communications striving to address such concerns, the impact of this threat on the medical transcription services market could be alleviated. 

Nevertheless, it is evident that offshoring could become an even more prominent trend in the medical transcription services market especially with developing European witnessing the rise of medical transcription service organizations (MTSOs). 

Browse Research Report on Global Medical Transcription Services Market: